Limits...
Inhibition of corneal neovascularization by topical and subconjunctival tigecycline.

Goktas S, Erdogan E, Sakarya R, Sakarya Y, Yılmaz M, Ozcimen M, Unlukal N, Alpfidan I, Tas F, Erdogan E, Bukus A, Ivacık IS - J Ophthalmol (2014)

Bottom Line: Materials and Methods.Control rats received topical (group 2) or subconjunctival (group 4) 0.9% saline.Results.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Konya Training and Research Hospital, Meram, 42090 Konya, Turkey.

ABSTRACT
Objective. To investigate the effects of topical and subconjunctival tigecycline on the prevention of corneal neovascularization. Materials and Methods. Following chemical burn, thirty-two rats were treated daily with topical instillation of 1 mg/mL tigecycline (group 1) or subconjunctival instillation of 1 mg/mL tigecycline (group 3) for 7 days. Control rats received topical (group 2) or subconjunctival (group 4) 0.9% saline. Digital photographs of the cornea were taken on the eighth day after treatment and analyzed to determine the percentage area of the cornea covered by neovascularization. Corneal sections were analyzed histopathologically. Results. The median percentages of corneal neovascularization in groups 1 and 3 were 48% (95% confidence interval (CI), 44.2-55.8%) and 33.5% (95% CI, 26.6-39.2%), respectively. The median percentages of corneal neovascularization of groups 1 and 3 were significantly lower than that of the control group (P = 0.03 and P < 0.001, resp.). Histologic examination of samples from groups 1 and 3 showed lower vascularity than that of control groups. Conclusion. Topical and subconjunctival administration of tigecycline seems to be showing promising therapeutic effects on the prevention of corneal neovascularization. Furthermore, subconjunctival administration of tigecycline is more potent than topical administration in the inhibition of corneal neovascularization.

No MeSH data available.


Related in: MedlinePlus

The percentage of corneal neovascularization by groups. Subconjunctivally tigecycline-treated eyes (group 3) showed significantly less corneal neovascularization than other groups.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4150514&req=5

fig2: The percentage of corneal neovascularization by groups. Subconjunctivally tigecycline-treated eyes (group 3) showed significantly less corneal neovascularization than other groups.

Mentions: The median percentages of corneal neovascularization are presented in Figure 2 and Table 2. The median percentages of corneal neovascularization in groups 1 and 3 (the study groups) were 48% (95% confidence interval (CI), 44.2–55.8%) and 33.5% (95% CI, 26.6–39.2%), respectively. The median percentages of corneal neovascularization in groups 2 and 4 (the control groups) were 67% (95% CI, 55.8–75.2%) and 70% (95% CI, 67.3–73.4%), respectively. The median percentages of corneal neovascularization of groups 1 and 3 were significantly lower than that of the control group (P = 0.03, P < 0.001, respectively). When groups 1 and 3 were compared with each other, group 3 showed significantly lower corneal neovascularization when compared with group 1 (P = 0.001).


Inhibition of corneal neovascularization by topical and subconjunctival tigecycline.

Goktas S, Erdogan E, Sakarya R, Sakarya Y, Yılmaz M, Ozcimen M, Unlukal N, Alpfidan I, Tas F, Erdogan E, Bukus A, Ivacık IS - J Ophthalmol (2014)

The percentage of corneal neovascularization by groups. Subconjunctivally tigecycline-treated eyes (group 3) showed significantly less corneal neovascularization than other groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4150514&req=5

fig2: The percentage of corneal neovascularization by groups. Subconjunctivally tigecycline-treated eyes (group 3) showed significantly less corneal neovascularization than other groups.
Mentions: The median percentages of corneal neovascularization are presented in Figure 2 and Table 2. The median percentages of corneal neovascularization in groups 1 and 3 (the study groups) were 48% (95% confidence interval (CI), 44.2–55.8%) and 33.5% (95% CI, 26.6–39.2%), respectively. The median percentages of corneal neovascularization in groups 2 and 4 (the control groups) were 67% (95% CI, 55.8–75.2%) and 70% (95% CI, 67.3–73.4%), respectively. The median percentages of corneal neovascularization of groups 1 and 3 were significantly lower than that of the control group (P = 0.03, P < 0.001, respectively). When groups 1 and 3 were compared with each other, group 3 showed significantly lower corneal neovascularization when compared with group 1 (P = 0.001).

Bottom Line: Materials and Methods.Control rats received topical (group 2) or subconjunctival (group 4) 0.9% saline.Results.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Konya Training and Research Hospital, Meram, 42090 Konya, Turkey.

ABSTRACT
Objective. To investigate the effects of topical and subconjunctival tigecycline on the prevention of corneal neovascularization. Materials and Methods. Following chemical burn, thirty-two rats were treated daily with topical instillation of 1 mg/mL tigecycline (group 1) or subconjunctival instillation of 1 mg/mL tigecycline (group 3) for 7 days. Control rats received topical (group 2) or subconjunctival (group 4) 0.9% saline. Digital photographs of the cornea were taken on the eighth day after treatment and analyzed to determine the percentage area of the cornea covered by neovascularization. Corneal sections were analyzed histopathologically. Results. The median percentages of corneal neovascularization in groups 1 and 3 were 48% (95% confidence interval (CI), 44.2-55.8%) and 33.5% (95% CI, 26.6-39.2%), respectively. The median percentages of corneal neovascularization of groups 1 and 3 were significantly lower than that of the control group (P = 0.03 and P < 0.001, resp.). Histologic examination of samples from groups 1 and 3 showed lower vascularity than that of control groups. Conclusion. Topical and subconjunctival administration of tigecycline seems to be showing promising therapeutic effects on the prevention of corneal neovascularization. Furthermore, subconjunctival administration of tigecycline is more potent than topical administration in the inhibition of corneal neovascularization.

No MeSH data available.


Related in: MedlinePlus